Tag Archives: resistant hypertension

Professor Christopher Miller HFpEF on the rise: navigating the heterogeneity In an engaging opening talk, Professor Christopher Miller (University of Manchester) revealed heart failure with preserved ejection fraction (HFpEF) as the dominant form of heart failure (HF), rising by 10% every decade. Over 70% of patients with HF have HFpEF, most of whom are over 65 years of age experiencing complex comorbidities. The diagnostic challenges in heterogeneous groups were discussed against the background of the diagnostic criteria provided by European Society of Cardiology (ESC)1 as some patients with clinical signs of HFpEF show normal

The Congress offers a unique opportunity to showcase therapeutic and diagnostic advances, alongside cutting edge, bench- to-bedside science. There are five days of scientific sessions covering 150 cardiovascular topics with over 500 expert sessions. This year over 11,000 abstracts were submitted, and the theme is ‘Environment and the heart’. We at the BCS are holding dedicated sessions at the Congress, and on Saturday 29th August we are hosting a General Cardiology Day for General Practitioners and Allied Professionals, so do encourage your colleagues and primary care colleagues to join us. Extracurricular activities include a series of e

Dr Melvin D Lobo (William Harvey Heart Centre, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London) The past three years has serendipitously seen the emergence of a novel class of device therapies for hypertension with renal sympathetic denervation (RSD) and baroreflex activation therapy currently leading the way. The intense interest in RSD is reflected in the fact that there are now more than 60 device manufacturers competing in this environment to produce technologies that cause renal nerve destruction through a variety of energy modalities based upon the fact that renal nerve

(more…)

Highlights of the American Heart Association 2010 meeting held in November 2010, in Chicago, USA, included a breakthrough for the treatment of resistant hypertension, and another oral anticoagulant that could be used instead of warfarin in atrial fibrillation patients, without the need for monitoring. RAFT: CRT reduces deaths and hospitalisations in mild heart failure Adding cardiac-resynchronisation therapy (CRT) to implantable cardioverter defibrillator (ICD) and medication, led to a reduction in deaths and heart failure hospitalistions among patients with mild-to-moderate symptoms of heart failure in the RAFT (Resynchronisation-Defibrilla